# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| | | |
|---|---|---|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of the participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | $U_{AV}$ = expanded uncertainty of the assigned value (k = 2) | |

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability: AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability: AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(121) Total T3** [nmol/L] | | | | 169 | | | | | | | 162 | 142 | 88% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 6,50 | 0,69 | 11 | 169 | | | | | | | 162 | 151 | 93% | | | | | | 0 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 6,20 | 0,15 | 2,4 | 5 | 0 CVPG | 6,2 | 0,42 | 15% | 5,27 | 7,13 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 5,76 | 0,55 | 9,5 | 29 | 0 CVPG | 5,76 | 0,25 | 15% | 4,89 | 6,63 | 29 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 5,96 | 0,35 | 5,9 | 16 | 0 CVPG | 5,96 | 0,22 | 15% | 5,06 | 6,86 | 16 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 5,99 | 0,52 | 8,7 | 13 | 0 CVPG | 5,99 | 0,36 | 15% | 5,09 | 6,89 | 13 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 7,44 | 0,37 | 5,0 | 5 | 0 CVPG | 7,44 | 1,0 | 15% | 6,32 | 8,56 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 6,85 | 0,31 | 4,5 | 60 | 0 CVPG | 6,85 | 0,097 | 15% | 5,82 | 7,88 | 60 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 6,58 | 0,68 | 10 | 11 | 0 CVPG | 6,58 | 0,50 | 15% | 5,59 | 7,57 | 11 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 6,99 | 0,41 | 5,9 | 23 | 0 CVPG | 6,99 | 0,21 | 15% | 5,94 | 8,04 | 23 | | | | | | | | | | |
| Other | | | | 7 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | 2x 1/36, 2x 3/15, 2x 4/164, 1x 6/60 | | | | | | | | | | | | | | | | |
| **Sample B** | 9,98 | 1,3 | 13 | 169 | | | | | | | 162 | 148 | 91% | | | | | | 0 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 9,81 | 0,36 | 3,6 | 5 | 0 CVPG | 9,81 | 1,0 | 15% | 8,33 | 11,3 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 8,66 | 0,75 | 8,6 | 29 | 0 CVPG | 8,66 | 0,34 | 15% | 7,36 | 9,96 | 29 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 9,78 | 0,88 | 9,0 | 16 | 0 CVPG | 9,78 | 0,54 | 15% | 8,31 | 11,3 | 16 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 9,05 | 0,31 | 3,4 | 13 | 0 CVPG | 9,05 | 0,21 | 15% | 7,69 | 10,5 | 13 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 11,9 | 0,15 | 1,2 | 5 | 0 CVPG | 11,9 | 0,42 | 15% | 10,1 | 13,7 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 10,0 | 0,02 | 0,23 | 60 | 0 CVPG | 10 | ,0072 | 15% | 8,5 | 11,5 | 60 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 10,4 | 1,1 | 10 | 11 | 0 CVPG | 10,4 | 0,78 | 15% | 8,84 | 12 | 11 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 11,8 | 0,67 | 5,7 | 23 | 0 CVPG | 11,8 | 0,34 | 15% | 10 | 13,6 | 23 | | | | | | | | | | |
| Other | | | | 7 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | 2x 1/36, 2x 3/15, 2x 4/164, 1x 6/60 | | | | | | | | | | | | | | | | |
| **(122) Total T4** [nmol/L] | | | | 152 | | | | | | | 138 | 126 | 91% | | | | | | 152 | 143 | 94% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 125 | 8,6 | 6,9 | 152 | | | | | | | 138 | 130 | 94% | CRV 132,8 | 1,4 | 17% | 110 | 156 | 152 | 145 | 95% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 121 | 5,3 | 4,4 | 31 | 0 CVPG | 121 | 2,3 | 13% | 105 | 137 | 31 | | | | | | | | 31 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 121 | 10 | 8,6 | 14 | 0 CVPG | 121 | 6,8 | 13% | 105 | 137 | 14 | | | | | | | | 14 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 129 | 12 | 9,1 | 15 | 0 CVPG | 129 | 7,4 | 13% | 112 | 146 | 15 | | | | | | | | 15 | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | | | | | | | | Traceability | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
| **(122) Total T4** [nmol/L] | | | | 152 | | | | | | | | 138 | 126 | 91% | | | | | | | 152 | 143 | 94% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 125 | 8,6 | 6,9 | 152 | | | | | | | | 138 | 130 | 94% | CRV | 132,8 | 1,4 | 17% | 110 | 156 | 152 | 145 | 95% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 136 | 3,7 | 2,7 | 5 | 0 | CVPG | 136 | 10 | 13% | 118 | 154 | 5 | | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 126 | 6,5 | 5,1 | 45 | 0 | CVPG | 126 | 2,4 | 13% | 109 | 143 | 45 | | | | | | | | | 45 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 123 | 5,4 | 4,4 | 9 | 0 | CVPG | 123 | 6,7 | 13% | 107 | 139 | 9 | | | | | | | | | 9 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 127 | 13 | 10 | 19 | 0 | CVPG | 127 | 7,5 | 13% | 110 | 144 | 19 | | | | | | | | | 19 | | |
| Other | | | | 14 | 0 | 2x 1/36, 1x 2/26, 2x 2/58, 1x 2/66, 2x 3/15, 4x 3/25, 2x 4/164 | | | | | | 0 | | | 2x 1/36, 1x 2/26, 2x 2/58, 1x 2/66, 2x 3/15, 4x 3/25, 2x 4/164 | | | | | | 14 | | |
| **Sample B** | 94,1 | 6,1 | 6,5 | 152 | | | | | | | | 138 | 129 | 93% | CRV | 100,6 | 1,0 | 17% | 83,4 | 118 | 152 | 148 | 97% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 90,0 | 4,4 | 4,9 | 31 | 0 | CVPG | 90 | 1,9 | 13% | 78,3 | 102 | 31 | | | | | | | | | 31 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 94,1 | 6,1 | 6,5 | 14 | 0 | CVPG | 94,1 | 4,0 | 13% | 81,8 | 107 | 14 | | | | | | | | | 14 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 94,4 | 6,8 | 7,2 | 15 | 1 | CVPG | 94,4 | 4,5 | 13% | 82,1 | 107 | 15 | | | | | | | | | 15 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 100 | 1,3 | 1,3 | 5 | 0 | CVPG | 100 | 3,8 | 13% | 87 | 113 | 5 | | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 96,1 | 5,6 | 5,8 | 45 | 0 | CVPG | 96,1 | 2,0 | 13% | 83,6 | 109 | 45 | | | | | | | | | 45 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 92,4 | 3,7 | 4,0 | 9 | 0 | CVPG | 92,4 | 4,6 | 13% | 80,3 | 105 | 9 | | | | | | | | | 9 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 95,1 | 8,7 | 9,2 | 19 | 0 | CVPG | 95,1 | 4,9 | 13% | 82,7 | 108 | 19 | | | | | | | | | 19 | | |
| Other | | | | 14 | 0 | 2x 1/36, 1x 2/26, 2x 2/58, 1x 2/66, 2x 3/15, 4x 3/25, 2x 4/164 | | | | | | 0 | | | 2x 1/36, 1x 2/26, 2x 2/58, 1x 2/66, 2x 3/15, 4x 3/25, 2x 4/164 | | | | | | 14 | | |
| **(123) TSH** [mU/L] | | | | 1670 | | | | | | | | 1653 | 1594 | 96% | | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 26,0 | 3,2 | 12 | 1670 | | | | | | | | 1653 | 1620 | 98% | | | | | | | 0 | | |
| (1) RIA (IRMA); (24) B.R.A.H.M.S. | 36,4 | 2,1 | 5,8 | 38 | 0 | CVPG | 36,4 | 0,84 | 14% | 31,3 | 41,5 | 38 | | | | | | | | | | | |
| (1) RIA (IRMA); (87) Euroimmun | 31,9 | 1,7 | 5,3 | 10 | 0 | CVPG | 31,9 | 1,3 | 14% | 27,4 | 36,4 | 10 | | | | | | | | | | | |
| (1) RIA (IRMA); (146) MEDIPAN Diagnostica | 35,4 | 2,9 | 8,2 | 7 | 0 | CVPG | 35,4 | 2,8 | 14% | 30,4 | 40,4 | 7 | | | | | | | | | | | |
| (1) RIA (IRMA); (214) Demeditec | 24,8 | 1,9 | 7,8 | 28 | 0 | CVPG | 24,8 | 0,89 | 14% | 21,3 | 28,3 | 28 | | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 23,2 | 0,25 | 1,1 | 21 | 0 | CVPG | 23,2 | 0,14 | 14% | 19,9 | 26,5 | 21 | | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 29,8 | 1,4 | 4,6 | 36 | 0 | CVPG | 29,8 | 0,56 | 14% | 25,6 | 34 | 36 | | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 25,8 | 2,1 | 8,3 | 20 | 0 | CVPG | 25,8 | 1,2 | 14% | 22,1 | 29,5 | 20 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 20,6 | 1,0 | 4,9 | 247 | 0 | CVPG | 20,6 | 0,16 | 14% | 17,7 | 23,5 | 247 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 24,4 | 1,4 | 5,9 | 143 | 0 | CVPG | 24,4 | 0,29 | 14% | 20,9 | 27,9 | 143 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 23,9 | 1,7 | 7,1 | 95 | 0 | CVPG | 23,9 | 0,43 | 14% | 20,5 | 27,3 | 95 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 26,4 | 1,1 | 4,2 | 8 | 0 | CVPG | 26,4 | 0,85 | 14% | 22,7 | 30,1 | 8 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 27,4 | 0,94 | 3,4 | 720 | 0 | CVPG | 27,4 | 0,085 | 14% | 23,5 | 31,3 | 720 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 28,4 | 1,2 | 4,3 | 80 | 0 | CVPG | 28,4 | 0,34 | 14% | 24,4 | 32,4 | 80 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 25,3 | 1,0 | 4,1 | 48 | 0 | CVPG | 25,3 | 0,37 | 14% | 21,7 | 28,9 | 48 | | | | | | | | | | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(123) TSH** [mU/L] | | | | 1670 | | | | | | | 1653 | 1594 | 96% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 26,0 | 3,2 | 12 | 1670 | | | | | | | 1653 | 1620 | 98% | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 32,0 | 1,7 | 5,4 | 24 | 0 | CVPG 32 | 0,86 | 14% | 27,5 | 36,5 | 24 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 24,9 | 0,97 | 3,9 | 94 | 0 | CVPG 24,9 | 0,25 | 14% | 21,4 | 28,4 | 94 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (257) Siemens (2) | 31,4 | 1,8 | 5,8 | 34 | 0 | CVPG 31,4 | 0,76 | 14% | 27 | 35,8 | 34 | | | | | | | | | | |
| Other | | | | 17 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | 1x 1/12, 4x 1/36, 2x 2/26, 1x 2/60, 1x 2/134, 2x 2/149, 2x 4/15, 4x 4/98 | | | | | | | | | | | | | | | |
| **Sample B** | 5,07 | 0,63 | 12 | 1670 | | | | | | | 1653 | 1614 | 98% | | | | | | 0 | | |
| (1) RIA (IRMA); (24) B.R.A.H.M.S. | 7,24 | 0,36 | 4,9 | 38 | 0 | CVPG 7,24 | 0,14 | 14% | 6,22 | 8,26 | 38 | | | | | | | | | | |
| (1) RIA (IRMA); (87) Euroimmun | 6,86 | 0,14 | 2,1 | 10 | 0 | CVPG 6,86 | 0,11 | 14% | 5,89 | 7,83 | 10 | | | | | | | | | | |
| (1) RIA (IRMA); (146) MEDIPAN Diagnostica | 6,85 | 0,40 | 5,8 | 7 | 0 | CVPG 6,85 | 0,39 | 14% | 5,89 | 7,81 | 7 | | | | | | | | | | |
| (1) RIA (IRMA); (214) Demeditec | 4,86 | 0,25 | 5,0 | 28 | 0 | CVPG 4,86 | 0,11 | 14% | 4,17 | 5,55 | 28 | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 3,88 | 0,09 | 2,5 | 21 | 0 | CVPG 3,88 | 0,053 | 14% | 3,33 | 4,43 | 21 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 5,83 | 0,30 | 5,2 | 36 | 0 | CVPG 5,83 | 0,12 | 14% | 5,01 | 6,65 | 36 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 4,99 | 0,59 | 12 | 20 | 0 | CVPG 4,99 | 0,33 | 14% | 4,29 | 5,69 | 20 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 4,13 | 0,25 | 6,1 | 247 | 0 | CVPG 4,13 | 0,039 | 14% | 3,55 | 4,71 | 247 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 4,71 | 0,26 | 5,5 | 143 | 0 | CVPG 4,71 | 0,053 | 14% | 4,05 | 5,37 | 143 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 5,02 | 0,36 | 7,1 | 95 | 1 | CVPG 5,02 | 0,091 | 14% | 4,31 | 5,73 | 95 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 5,11 | 0,27 | 5,2 | 8 | 0 | CVPG 5,11 | 0,20 | 14% | 4,39 | 5,83 | 8 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 5,40 | 0,18 | 3,3 | 720 | 0 | CVPG 5,4 | 0,017 | 14% | 4,64 | 6,16 | 720 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 4,76 | 0,22 | 4,7 | 80 | 0 | CVPG 4,76 | 0,061 | 14% | 4,09 | 5,43 | 80 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 4,80 | 0,19 | 4,0 | 48 | 0 | CVPG 4,8 | 0,068 | 14% | 4,12 | 5,48 | 48 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 6,59 | 0,39 | 6,0 | 24 | 0 | CVPG 6,59 | 0,20 | 14% | 5,66 | 7,52 | 24 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 4,77 | 0,20 | 4,1 | 94 | 0 | CVPG 4,77 | 0,050 | 14% | 4,1 | 5,44 | 94 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (257) Siemens (2) | 6,09 | 0,30 | 5,0 | 34 | 0 | CVPG 6,09 | 0,13 | 14% | 5,23 | 6,95 | 34 | | | | | | | | | | |
| Other | | | | 17 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | 1x 1/12, 4x 1/36, 2x 2/26, 1x 2/60, 1x 2/134, 2x 2/149, 2x 4/15, 4x 4/98 | | | | | | | | | | | | | | | |
| **(124) Free T4** [pmol/L] | | | | 1465 | | | | | | | 1454 | 1407 | 97% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 22,6 | 3,2 | 14 | 1465 | | | | | | | 1454 | 1424 | 98% | | | | | | 0 | | |
| (1) RIA (IRMA); (24) B.R.A.H.M.S. | 23,2 | 1,6 | 6,8 | 39 | 0 | CVPG 23,2 | 0,62 | 13% | 20,1 | 26,3 | 39 | | | | | | | | | | |
| (1) RIA (IRMA); (36) Immunotech | 19,7 | 1,1 | 5,7 | 5 | 0 | CVPG 19,7 | 3,1 | 13% | 17,1 | 22,3 | 5 | | | | | | | | | | |
| (1) RIA (IRMA); (87) Euroimmun | 23,8 | 0,84 | 3,5 | 10 | 0 | CVPG 23,8 | 0,65 | 13% | 20,7 | 26,9 | 10 | | | | | | | | | | |
| (1) RIA (IRMA); (146) MEDIPAN Diagnostica | 23,7 | 1,7 | 7,2 | 8 | 0 | CVPG 23,7 | 1,3 | 13% | 20,6 | 26,8 | 8 | | | | | | | | | | |
| (1) RIA (IRMA); (214) Demeditec | 22,1 | 1,3 | 5,7 | 29 | 0 | CVPG 22,1 | 0,57 | 13% | 19,2 | 25 | 29 | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 21,7 | 1,2 | 5,7 | 5 | 0 | CVPG 21,7 | 3,5 | 13% | 18,8 | 24,6 | 5 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 27,1 | 1,2 | 4,6 | 23 | 0 | CVPG 27,1 | 0,63 | 13% | 23,5 | 30,7 | 23 | | | | | | | | | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(124) Free T4** [pmol/L] | | | | 1465 | | | | | | | 1454 | 1407 | 97% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 22,6 | 3,2 | 14 | 1465 | | | | | | | 1454 | 1424 | 98% | | | | | | 0 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 24,5 | 1,3 | 5,3 | 17 | 0 | CVPG 24,5 | 0,77 | 13% | 21,3 | 27,7 | 17 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 17,1 | 0,73 | 4,3 | 214 | 0 | CVPG 17,1 | 0,12 | 13% | 14,8 | 19,4 | 214 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 20,4 | 1,2 | 5,7 | 126 | 0 | CVPG 20,4 | 0,25 | 13% | 17,7 | 23,1 | 126 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 26,8 | 0,87 | 3,2 | 81 | 0 | CVPG 26,8 | 0,24 | 13% | 23,3 | 30,3 | 81 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 27,8 | 1,3 | 4,5 | 6 | 0 | CVPG 27,8 | 1,8 | 13% | 24,1 | 31,5 | 6 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 24,4 | 1,2 | 4,7 | 643 | 0 | CVPG 24,4 | 0,11 | 13% | 21,2 | 27,6 | 643 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 20,4 | 0,94 | 4,6 | 63 | 0 | CVPG 20,4 | 0,29 | 13% | 17,7 | 23,1 | 63 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 21,8 | 1,1 | 5,1 | 45 | 0 | CVPG 21,8 | 0,41 | 13% | 18,9 | 24,7 | 45 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 23,2 | 1,5 | 6,3 | 23 | 0 | CVPG 23,2 | 0,75 | 13% | 20,1 | 26,3 | 23 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 21,2 | 1,1 | 5,4 | 117 | 0 | CVPG 21,2 | 0,26 | 13% | 18,4 | 24 | 117 | | | | | | | | | | |
| Other | | | | 11 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | 1x 1/12, 1x 1/164, 2x 2/26, 1x 2/60, 1x 2/134, 1x 3/60, 2x 4/15, 2x 4/98 | | | | | | | | | | | | | | | | |
| **Sample B** | 18,5 | 2,7 | 15 | 1465 | | | | | | | 1454 | 1419 | 98% | | | | | | 0 | | |
| (1) RIA (IRMA); (24) B.R.A.H.M.S. | 19,7 | 1,5 | 7,5 | 39 | 0 | CVPG 19,7 | 0,58 | 13% | 17,1 | 22,3 | 39 | | | | | | | | | | |
| (1) RIA (IRMA); (36) Immunotech | 18,6 | 0,96 | 5,2 | 5 | 0 | CVPG 18,6 | 2,7 | 13% | 16,1 | 21,1 | 5 | | | | | | | | | | |
| (1) RIA (IRMA); (87) Euroimmun | 20,3 | 0,86 | 4,2 | 10 | 0 | CVPG 20,3 | 0,66 | 13% | 17,6 | 23 | 10 | | | | | | | | | | |
| (1) RIA (IRMA); (146) MEDIPAN Diagnostica | 19,0 | 0,90 | 4,7 | 8 | 0 | CVPG 19 | 0,68 | 13% | 16,5 | 21,5 | 8 | | | | | | | | | | |
| (1) RIA (IRMA); (214) Demeditec | 19,0 | 1,4 | 7,4 | 29 | 0 | CVPG 19 | 0,64 | 13% | 16,5 | 21,5 | 29 | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 18,1 | 1,8 | 10 | 5 | 0 | CVPG 18,1 | 5,1 | 13% | 15,7 | 20,5 | 5 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 22,1 | 1,1 | 5,0 | 23 | 0 | CVPG 22,1 | 0,57 | 13% | 19,2 | 25 | 23 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 18,9 | 1,4 | 7,7 | 17 | 0 | CVPG 18,9 | 0,86 | 13% | 16,4 | 21,4 | 17 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 13,8 | 0,62 | 4,5 | 214 | 0 | CVPG 13,8 | 0,10 | 13% | 12 | 15,6 | 214 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 15,7 | 1,1 | 6,8 | 126 | 0 | CVPG 15,7 | 0,23 | 13% | 13,6 | 17,8 | 126 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 22,3 | 0,96 | 4,3 | 81 | 0 | CVPG 22,3 | 0,26 | 13% | 19,4 | 25,2 | 81 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 19,9 | 1,1 | 5,6 | 6 | 0 | CVPG 19,9 | 1,6 | 13% | 17,3 | 22,5 | 6 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 19,7 | 0,94 | 4,8 | 643 | 0 | CVPG 19,7 | 0,091 | 13% | 17,1 | 22,3 | 643 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 16,4 | 0,70 | 4,3 | 63 | 0 | CVPG 16,4 | 0,22 | 13% | 14,2 | 18,6 | 63 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 19,2 | 0,91 | 4,7 | 45 | 0 | CVPG 19,2 | 0,33 | 13% | 16,7 | 21,7 | 45 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 18,8 | 1,1 | 5,8 | 23 | 0 | CVPG 18,8 | 0,56 | 13% | 16,3 | 21,3 | 23 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 18,4 | 1,0 | 5,6 | 117 | 0 | CVPG 18,4 | 0,23 | 13% | 16 | 20,8 | 117 | | | | | | | | | | |
| Other | | | | 11 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | 1x 1/12, 1x 1/164, 2x 2/26, 1x 2/60, 1x 2/134, 1x 3/60, 2x 4/15, 2x 4/98 | | | | | | | | | | | | | | | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(125) Free T3** [pmol/L] | | | | 1346 | | | | | | | 1337 | 1295 | 97% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 22,3 | 4,3 | 19 | 1346 | | | | | | | 1337 | 1315 | 98% | | | | | | 0 | | |
| (1) RIA (IRMA); (24) B.R.A.H.M.S. | 23,4 | 1,4 | 5,8 | 37 | 0 CVPG | 23,4 | 0,55 | 15% | 19,8 | 27 | 37 | | | | | | | | | | |
| (1) RIA (IRMA); (36) Immunotech | 18,8 | 2,2 | 12 | 8 | 0 CVPG | 18,8 | 1,7 | 15% | 15,9 | 21,7 | 8 | | | | | | | | | | |
| (1) RIA (IRMA); (87) Euroimmun | 20,1 | 1,6 | 7,8 | 9 | 0 CVPG | 20,1 | 1,9 | 15% | 17 | 23,2 | 9 | | | | | | | | | | |
| (1) RIA (IRMA); (146) MEDIPAN Diagnostica | 20,9 | 2,1 | 10 | 8 | 0 CVPG | 20,9 | 1,6 | 15% | 17,7 | 24,1 | 8 | | | | | | | | | | |
| (1) RIA (IRMA); (214) Demeditec | 19,9 | 1,7 | 8,6 | 30 | 0 CVPG | 19,9 | 0,77 | 15% | 16,9 | 22,9 | 30 | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 20,0 | 0,23 | 1,1 | 5 | 0 CVPG | 20 | 0,65 | 15% | 17 | 23 | 5 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 18,8 | 1,7 | 9,1 | 25 | 0 CVPG | 18,8 | 0,84 | 15% | 15,9 | 21,7 | 25 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 20,0 | 1,2 | 5,9 | 12 | 0 CVPG | 20 | 0,83 | 15% | 17 | 23 | 12 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 19,9 | 1,2 | 5,8 | 170 | 0 CVPG | 19,9 | 0,22 | 15% | 16,9 | 22,9 | 170 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 16,7 | 1,2 | 7,3 | 115 | 0 CVPG | 16,7 | 0,28 | 15% | 14,1 | 19,3 | 115 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 19,8 | 1,4 | 7,2 | 72 | 0 CVPG | 19,8 | 0,41 | 15% | 16,8 | 22,8 | 72 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 21,3 | 1,0 | 4,9 | 8 | 0 CVPG | 21,3 | 0,79 | 15% | 18,1 | 24,5 | 8 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 26,1 | 0,79 | 3,0 | 593 | 0 CVPG | 26,1 | 0,079 | 15% | 22,1 | 30,1 | 593 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 21,5 | 0,64 | 3,0 | 46 | 0 CVPG | 21,5 | 0,23 | 15% | 18,2 | 24,8 | 46 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (154) Abbott (2) | 20,0 | 1,3 | 6,6 | 20 | 0 CVPG | 20 | 0,72 | 15% | 17 | 23 | 20 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 18,4 | 0,70 | 3,8 | 43 | 0 CVPG | 18,4 | 0,26 | 15% | 15,6 | 21,2 | 43 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 19,0 | 0,79 | 4,2 | 24 | 0 CVPG | 19 | 0,40 | 15% | 16,1 | 21,9 | 24 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 17,8 | 0,82 | 4,6 | 112 | 0 CVPG | 17,8 | 0,19 | 15% | 15,1 | 20,5 | 112 | | | | | | | | | | |
| Other | | | | 9 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | 1x 1/12, 2x 2/26, 1x 2/60, 1x 2/134, 2x 4/15, 2x 4/98 | | | | | | | | | | | | | | | |
| **Sample B** | 34,2 | 7,2 | 21 | 1346 | | | | | | | 1337 | 1311 | 98% | | | | | | 0 | | |
| (1) RIA (IRMA); (24) B.R.A.H.M.S. | 33,5 | 2,4 | 7,1 | 37 | 0 CVPG | 33,5 | 0,96 | 15% | 28,4 | 38,6 | 37 | | | | | | | | | | |
| (1) RIA (IRMA); (36) Immunotech | 26,4 | 3,3 | 13 | 8 | 0 CVPG | 26,4 | 2,5 | 15% | 22,4 | 30,4 | 8 | | | | | | | | | | |
| (1) RIA (IRMA); (87) Euroimmun | 28,6 | 2,2 | 7,8 | 9 | 0 CVPG | 28,6 | 2,7 | 15% | 24,3 | 32,9 | 9 | | | | | | | | | | |
| (1) RIA (IRMA); (146) MEDIPAN Diagnostica | 28,0 | 0,69 | 2,4 | 8 | 0 CVPG | 28 | 0,52 | 15% | 23,8 | 32,2 | 8 | | | | | | | | | | |
| (1) RIA (IRMA); (214) Demeditec | 26,7 | 1,9 | 7,1 | 30 | 0 CVPG | 26,7 | 0,85 | 15% | 22,6 | 30,8 | 30 | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 30,3 | 0,91 | 3,0 | 5 | 0 CVPG | 30,3 | 2,6 | 15% | 25,7 | 34,9 | 5 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 26,8 | 2,0 | 7,4 | 25 | 0 CVPG | 26,8 | 0,98 | 15% | 22,7 | 30,9 | 25 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 32,4 | 1,9 | 5,9 | 12 | 0 CVPG | 32,4 | 1,4 | 15% | 27,5 | 37,3 | 12 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 29,9 | 1,3 | 4,4 | 170 | 1 CVPG | 29,9 | 0,25 | 15% | 25,4 | 34,4 | 170 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 26,7 | 1,4 | 5,4 | 115 | 0 CVPG | 26,7 | 0,33 | 15% | 22,6 | 30,8 | 115 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 31,4 | 2,6 | 8,1 | 72 | 0 CVPG | 31,4 | 0,74 | 15% | 26,6 | 36,2 | 72 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 30,3 | 0,89 | 2,9 | 8 | 0 CVPG | 30,3 | 0,68 | 15% | 25,7 | 34,9 | 8 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 40,3 | 1,2 | 3,1 | 593 | 0 CVPG | 40,3 | 0,12 | 15% | 34,2 | 46,4 | 593 | | | | | | | | | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(125) Free T3** [pmol/L] | | | | 1346 | | | | | | | 1337 | 1295 | 97% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample B** | 34,2 | 7,2 | 21 | 1346 | | | | | | | 1337 | 1311 | 98% | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 35,7 | 1,1 | 3,0 | 46 | 0 | CVPG 35,7 | 0,38 | 15% | 30,3 | 41,1 | 46 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (154) Abbott (2) | 48,0 | 3,7 | 7,8 | 20 | 0 | CVPG 48 | 2,0 | 15% | 40,8 | 55,2 | 20 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 27,8 | 2,0 | 7,3 | 43 | 0 | CVPG 27,8 | 0,76 | 15% | 23,6 | 32 | 43 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 25,7 | 1,1 | 4,2 | 24 | 0 | CVPG 25,7 | 0,54 | 15% | 21,8 | 29,6 | 24 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 26,4 | 2,4 | 8,9 | 112 | 0 | CVPG 26,4 | 0,55 | 15% | 22,4 | 30,4 | 112 | | | | | | | | | | |
| Other | | | | 9 | 0 | 1x 1/12, 2x 2/26, 1x 2/60, 1x 2/134, 2x 4/15, 2x 4/98 | | | | | 0 | | | | | | | | | | |
| **(200) Ferritin** [µg/L] | | | | 883 | | | | | | | 865 | 845 | 98% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 478 | 67 | 14 | 883 | | | | | | | 865 | 855 | 99% | | | | | | 0 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 406 | 46 | 11 | 18 | 0 | CVPG 406 | 26 | 24% | 308 | 504 | 18 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 385 | 25 | 6,5 | 7 | 0 | CVPG 385 | 24 | 24% | 292 | 478 | 7 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 572 | 44 | 7,7 | 121 | 0 | CVPG 572 | 9,8 | 24% | 434 | 710 | 121 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 372 | 23 | 6,3 | 72 | 0 | CVPG 372 | 6,7 | 24% | 282 | 462 | 72 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 433 | 30 | 7,0 | 33 | 0 | CVPG 433 | 13 | 24% | 329 | 537 | 33 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 310 | 9,6 | 3,1 | 7 | 0 | CVPG 310 | 9,4 | 24% | 235 | 385 | 7 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 507 | 29 | 5,8 | 283 | 0 | CVPG 507 | 4,3 | 24% | 385 | 629 | 283 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 447 | 28 | 6,2 | 11 | 0 | CVPG 447 | 20 | 24% | 339 | 555 | 11 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 445 | 29 | 6,6 | 31 | 0 | CVPG 445 | 13 | 24% | 338 | 552 | 31 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 526 | 22 | 4,2 | 9 | 0 | CVPG 526 | 27 | 24% | 399 | 653 | 9 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 461 | 50 | 11 | 63 | 0 | CVPG 461 | 15 | 24% | 350 | 572 | 63 | | | | | | | | | | |
| (6) IMT, IMN; (58) Beckman Coulter (AU) | 428 | 13 | 3,1 | 44 | 0 | CVPG 428 | 4,9 | 24% | 325 | 531 | 44 | | | | | | | | | | |
| (6) IMT, IMN; (60) Roche | 473 | 26 | 5,5 | 152 | 0 | CVPG 473 | 5,2 | 24% | 359 | 587 | 152 | | | | | | | | | | |
| (6) IMT, IMN; (149) Siemens (Dade, BN, Dimension) | 383 | 14 | 3,7 | 7 | 0 | CVPG 383 | 14 | 24% | 291 | 475 | 7 | | | | | | | | | | |
| (6) IMT, IMN; (179) Siemens | 366 | 85 | 23 | 7 | 0 | CVPG 366 | 83 | 24% | 278 | 454 | 7 | | | | | | | | | | |
| Other | | | | 18 | 0 | 3x 1/36, 2x 2/60, 2x 2/66, 2x 2/149, 2x 4/15, 4x 6/1, 1x 6/5, 1x 6/12, 1x 6/178 | | | | | 0 | | | | | | | | | | |
| **Sample B** | 167 | 27 | 16 | 883 | | | | | | | 865 | 851 | 98% | | | | | | 0 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 138 | 18 | 13 | 18 | 0 | CVPG 138 | 10 | 24% | 104 | 172 | 18 | | | | | | | | | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 136 | 18 | 14 | 7 | 0 | CVPG 136 | 18 | 24% | 103 | 169 | 7 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 180 | 14 | 7,9 | 121 | 0 | CVPG 180 | 3,2 | 24% | 136 | 224 | 121 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 123 | 9,5 | 7,7 | 72 | 0 | CVPG 123 | 2,7 | 24% | 93,4 | 153 | 72 | | | | | | | | | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(200) Ferritin** [µg/L] | | | | 883 | | | | | | | 865 | 845 | 98% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample B** | 167 | 27 | 16 | 883 | | | | | | | 865 | 851 | 98% | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 143 | 14 | 10 | 33 | 0 | CVPG 143 | 6,1 | 24% | 108 | 178 | 33 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (40) Ortho Clinical Diagnostics | 100 | 11 | 11 | 7 | 0 | CVPG 100 | 11 | 24% | 76 | 124 | 7 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 184 | 14 | 7,4 | 283 | 0 | CVPG 184 | 2,0 | 24% | 139 | 229 | 283 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (149) Siemens (Dade, BN, Dimension) | 142 | 16 | 11 | 11 | 0 | CVPG 142 | 12 | 24% | 107 | 177 | 11 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 147 | 11 | 7,5 | 31 | 0 | CVPG 147 | 4,8 | 24% | 111 | 183 | 31 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 178 | 30 | 17 | 9 | 0 | CVPG 178 | 38 | 24% | 135 | 221 | 9 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 146 | 14 | 9,3 | 63 | 0 | CVPG 146 | 4,2 | 24% | 110 | 182 | 63 | | | | | | | | | | |
| (6) IMT, IMN; (58) Beckman Coulter (AU) | 154 | 12 | 8,0 | 44 | 0 | CVPG 154 | 4,5 | 24% | 117 | 191 | 44 | | | | | | | | | | |
| (6) IMT, IMN; (60) Roche | 178 | 14 | 8,0 | 152 | 0 | CVPG 178 | 2,8 | 24% | 135 | 221 | 152 | | | | | | | | | | |
| (6) IMT, IMN; (149) Siemens (Dade, BN, Dimension) | 137 | 13 | 9,2 | 7 | 0 | CVPG 137 | 12 | 24% | 104 | 170 | 7 | | | | | | | | | | |
| (6) IMT, IMN; (179) Siemens | 152 | 12 | 7,8 | 7 | 0 | CVPG 152 | 12 | 24% | 115 | 189 | 7 | | | | | | | | | | |
| Other | | | | 18 | 0 | 3x 1/36, 2x 2/60, 2x 2/66, 2x 2/149, 2x 4/15, 4x 6/1, 1x 6/5, 1x 6/12, 1x 6/178 | | | | | 0 | | | | | | | | | | |
| **(301) Cortisol** [nmol/L] | | | | 608 | | | | | | | 600 | 571 | 95% | | | | | | 608 | 567 | 93% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 570 | 61 | 11 | 608 | | | | | | | 600 | 579 | 97% | CRV 586,8 | 6,8 | 22% | 457 | 716 | 608 | 594 | 98% |
| (1) RIA (IRMA); (36) Immunotech | 624 | 40 | 6,5 | 7 | 0 | CVPG 624 | 39 | 16% | 524 | 724 | 7 | | | | | | | | 7 | | |
| (2) EIA (ELISA); (66) DRG | 643 | 4,1 | 0,64 | 5 | 0 | CVPG 643 | 12 | 16% | 540 | 746 | 5 | | | | | | | | 5 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 540 | 51 | 9,5 | 7 | 0 | CVPG 540 | 50 | 16% | 453 | 627 | 7 | | | | | | | | 7 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 508 | 23 | 4,5 | 98 | 0 | CVPG 508 | 5,6 | 16% | 426 | 590 | 98 | | | | | | | | 98 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 552 | 33 | 6,0 | 56 | 0 | CVPG 552 | 11 | 16% | 463 | 641 | 56 | | | | | | | | 56 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 524 | 36 | 6,8 | 78 | 0 | CVPG 524 | 9,9 | 16% | 440 | 608 | 78 | | | | | | | | 78 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 578 | 32 | 5,5 | 237 | 0 | CVPG 578 | 5,0 | 16% | 485 | 671 | 237 | | | | | | | | 237 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 659 | 46 | 7,0 | 30 | 0 | CVPG 659 | 21 | 16% | 553 | 765 | 30 | | | | | | | | 30 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 534 | 41 | 7,6 | 10 | 0 | CVPG 534 | 32 | 16% | 448 | 620 | 10 | | | | | | | | 10 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 650 | 49 | 7,5 | 72 | 0 | CVPG 650 | 14 | 16% | 546 | 754 | 72 | | | | | | | | 72 | | |
| Other | | | | 8 | 0 | 1x 1/29, 1x 2/26, 1x 2/60, 1x 2/214, 4x 3/25 | | | | | 0 | | | 1x 1/29, 1x 2/26, 1x 2/60, 1x 2/214, 4x 3/25 | | | | | 8 | | |
| **Sample B** | 731 | 80 | 11 | 608 | | | | | | | 600 | 579 | 97% | CRV 732,1 | 7,3 | 22% | 571 | 894 | 608 | 574 | 94% |
| (1) RIA (IRMA); (36) Immunotech | 857 | 44 | 5,1 | 7 | 0 | CVPG 857 | 42 | 16% | 719 | 995 | 7 | | | | | | | | 7 | | |
| (2) EIA (ELISA); (66) DRG | 806 | 4,1 | 0,51 | 5 | 0 | CVPG 806 | 12 | 16% | 677 | 935 | 5 | | | | | | | | 5 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 687 | 49 | 7,1 | 7 | 0 | CVPG 687 | 48 | 16% | 577 | 797 | 7 | | | | | | | | 7 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 674 | 30 | 4,4 | 98 | 0 | CVPG 674 | 7,4 | 16% | 566 | 782 | 98 | | | | | | | | 98 | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(301) Cortisol** [nmol/L] | | | | 608 | | | | | | | 600 | 571 | 95% | | | | | | 608 | 567 | 93% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample B** | 731 | 80 | 11 | 608 | | | | | | | 600 | 579 | 97% | CRV 732,1 | 7,3 | 22% | 571 | 894 | 608 | 574 | 94% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 738 | 54 | 7,3 | 56 | 0 | CVPG 738 | 18 | 16% | 619 | 857 | 56 | | | | | | | | 56 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 664 | 42 | 6,4 | 78 | 0 | CVPG 664 | 12 | 16% | 557 | 771 | 78 | | | | | | | | 78 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 718 | 42 | 5,8 | 237 | 0 | CVPG 718 | 6,6 | 16% | 603 | 833 | 237 | | | | | | | | 237 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 875 | 44 | 5,1 | 30 | 0 | CVPG 875 | 20 | 16% | 735 | 1020 | 30 | | | | | | | | 30 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 777 | 58 | 7,5 | 10 | 0 | CVPG 777 | 45 | 16% | 652 | 902 | 10 | | | | | | | | 10 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 853 | 53 | 6,2 | 72 | 0 | CVPG 853 | 15 | 16% | 716 | 990 | 72 | | | | | | | | 72 | | |
| Other | | | | 8 | 0 | | | | | | 0 | | | | | | | | 8 | | |
| | | | | | | 1x 1/29, 1x 2/26, 1x 2/60, 1x 2/214, 4x 3/25 | | | | | | | | 1x 1/29, 1x 2/26, 1x 2/60, 1x 2/214, 4x 3/25 | | | | | | | |
| **(302) 17-beta-estradiol** [pmol/L] | | | | 739 | | | | | | | 717 | 708 | 99% | | | | | | 739 | 722 | 98% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 1250 | 150 | 12 | 739 | | | | | | | 717 | 711 | 99% | CRV 1269 | 18 | 30% | 888 | 1650 | 739 | 730 | 99% |
| (2) EIA (ELISA); (66) DRG | 1080 | 52 | 4,8 | 35 | 0 | CVPG 1080 | 22 | 22% | 842 | 1320 | 35 | | | | | | | | 35 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 1070 | 71 | 6,6 | 30 | 0 | CVPG 1070 | 32 | 22% | 834 | 1310 | 30 | | | | | | | | 30 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 1210 | 84 | 6,9 | 9 | 0 | CVPG 1210 | 100 | 22% | 943 | 1480 | 9 | | | | | | | | 9 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 1090 | 61 | 5,6 | 109 | 0 | CVPG 1090 | 14 | 22% | 850 | 1330 | 109 | | | | | | | | 109 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 1340 | 59 | 4,4 | 68 | 0 | CVPG 1340 | 17 | 22% | 1040 | 1640 | 68 | | | | | | | | 68 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 1100 | 95 | 8,6 | 58 | 0 | CVPG 1100 | 31 | 22% | 858 | 1350 | 58 | | | | | | | | 58 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 1350 | 51 | 3,8 | 281 | 0 | CVPG 1350 | 7,5 | 22% | 1050 | 1650 | 281 | | | | | | | | 281 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 1370 | 60 | 4,4 | 40 | 0 | CVPG 1370 | 23 | 22% | 1060 | 1680 | 40 | | | | | | | | 40 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 1120 | 150 | 13 | 17 | 0 | CVPG 1120 | 89 | 22% | 873 | 1370 | 17 | | | | | | | | 17 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 1290 | 74 | 5,8 | 70 | 0 | CVPG 1290 | 22 | 22% | 1000 | 1580 | 70 | | | | | | | | 70 | | |
| Other | | | | 22 | 0 | | | | | | 0 | | | | | | | | 22 | | |
| | | | | | | 4x 1/36, 1x 1/185, 3x 1/218, 1x 2/26, 1x 2/60, 2x 2/134, 1x 2/214, 2x 4/15, 1x 4/66, 1x 4/98, 4x 4/149, 1x 6/60 | | | | | | | | 4x 1/36, 1x 1/185, 3x 1/218, 1x 2/26, 1x 2/60, 2x 2/134, 1x 2/214, 2x 4/15, 1x 4/66, 1x 4/98, 4x 4/149, 1x 6/60 | | | | | | | |
| **Sample B** | 855 | 97 | 11 | 739 | | | | | | | 717 | 712 | 99% | CRV 857 | 12 | 30% | 599 | 1120 | 739 | 727 | 98% |
| (2) EIA (ELISA); (66) DRG | 689 | 71 | 10 | 35 | 0 | CVPG 689 | 30 | 22% | 537 | 841 | 35 | | | | | | | | 35 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 712 | 51 | 7,1 | 30 | 0 | CVPG 712 | 23 | 22% | 555 | 869 | 30 | | | | | | | | 30 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 862 | 60 | 6,9 | 9 | 0 | CVPG 862 | 74 | 22% | 672 | 1060 | 9 | | | | | | | | 9 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 771 | 51 | 6,6 | 109 | 0 | CVPG 771 | 12 | 22% | 601 | 941 | 109 | | | | | | | | 109 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 922 | 47 | 5,1 | 68 | 0 | CVPG 922 | 14 | 22% | 719 | 1130 | 68 | | | | | | | | 68 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 754 | 80 | 11 | 58 | 0 | CVPG 754 | 26 | 22% | 588 | 920 | 58 | | | | | | | | 58 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 917 | 36 | 3,9 | 281 | 0 | CVPG 917 | 5,2 | 22% | 715 | 1120 | 281 | | | | | | | | 281 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 901 | 31 | 3,4 | 40 | 0 | CVPG 901 | 12 | 22% | 702 | 1100 | 40 | | | | | | | | 40 | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(302) 17-beta-estradiol** [pmol/L] | | | | 739 | | | | | | | 717 | 708 | 99% | | | | | | 739 | 722 | 98% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample B** | 855 | 97 | 11 | 739 | | | | | | | 717 | 712 | 99% | CRV 857 | 12 | 30% | 599 | 1120 | 739 | 727 | 98% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 778 | 63 | 8,1 | 17 | 0 | CVPG 778 | 38 | 22% | 606 | 950 | 17 | | | | | | | | 17 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 874 | 52 | 6,0 | 70 | 0 | CVPG 874 | 15 | 22% | 681 | 1070 | 70 | | | | | | | | 70 | | |
| Other | | | | 22 | 0 | | | | | | 0 | | | | | | | | 22 | | |
| | | | | | | 4x 1/36, 1x 1/185, 3x 1/218, 1x 2/26, 1x 2/60, 2x 2/134, 1x 2/214, 2x 4/15, 1x 4/66, 1x 4/98, 4x 4/149, 1x 6/60 | | | | | | | | 4x 1/36, 1x 1/185, 3x 1/218, 1x 2/26, 1x 2/60, 2x 2/134, 1x 2/214, 2x 4/15, 1x 4/66, 1x 4/98, 4x 4/149, 1x 6/60 | | | | | | | |
| **(303) Aldosterone** [nmol/L] | | | | 211 | | | | | | | 203 | 197 | 97% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 0,978 | 0,11 | 11 | 211 | | | | | | | 203 | 201 | 99% | | | | | | 0 | | |
| (1) RIA (IRMA); (36) Immunotech | 1,25 | 0,15 | 12 | 7 | 0 | CVPG 1,25 | 0,15 | 33% | 0,837 | 1,67 | 7 | | | | | | | | | | |
| (1) RIA (IRMA); (218) Immunotech (original) | 1,07 | 0,27 | 25 | 5 | 1 | CVPG 1,07 | 0,26 | 33% | 0,716 | 1,43 | 5 | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 0,955 | 0,02 | 2,3 | 5 | 0 | CVPG 0,955 | 0,063 | 33% | 0,639 | 1,28 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 0,947 | 0,09 | 9,9 | 151 | 0 | CVPG 0,947 | 0,019 | 33% | 0,634 | 1,26 | 151 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | 1,07 | 0,05 | 5,4 | 35 | 0 | CVPG 1,07 | 0,024 | 33% | 0,716 | 1,43 | 35 | | | | | | | | | | |
| Other | | | | 8 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | 2x 1/185, 1x 1/214, 1x 2/26, 1x 2/134, 1x 2/183, 1x 4/98, 1x 4/999 | | | | | | | | | | | | | | | | |
| **Sample B** | 0,251 | 0,04 | 16 | 211 | | | | | | | 203 | 197 | 97% | | | | | | 0 | | |
| (1) RIA (IRMA); (36) Immunotech | 0,365 | 0,13 | 34 | 7 | 0 | CVPG 0,365 | 0,12 | 33% | 0,244 | 0,486 | 7 | | | | | | | | | | |
| (1) RIA (IRMA); (218) Immunotech (original) | 0,305 | 0,03 | 12 | 5 | 1 | CVPG 0,305 | 0,037 | 33% | 0,204 | 0,406 | 5 | | | | | | | | | | |
| (2) EIA (ELISA); (66) DRG | 0,366 | 0,03 | 10 | 5 | 0 | CVPG 0,366 | 0,11 | 33% | 0,245 | 0,487 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 0,250 | 0,03 | 13 | 151 | 0 | CVPG 0,25 | ,0065 | 33% | 0,167 | 0,333 | 151 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | 0,217 | 0,04 | 19 | 35 | 0 | CVPG 0,217 | 0,018 | 33% | 0,145 | 0,289 | 35 | | | | | | | | | | |
| Other | | | | 8 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | 2x 1/185, 1x 1/214, 1x 2/26, 1x 2/134, 1x 2/183, 1x 4/98, 1x 4/999 | | | | | | | | | | | | | | | | |
| **(304) Progesterone** [nmol/L] | | | | 659 | | | | | | | 650 | 621 | 96% | | | | | | 659 | 549 | 83% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 44,6 | 8,2 | 18 | 659 | | | | | | | 650 | 642 | 99% | CRV 45,07 | 0,56 | 26% | 33,3 | 56,8 | 659 | 614 | 93% |
| (2) EIA (ELISA); (66) DRG | 46,5 | 0,70 | 1,5 | 34 | 0 | CVPG 46,5 | 0,29 | 20% | 37,2 | 55,8 | 34 | | | | | | | | 34 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 58,6 | 3,4 | 5,8 | 23 | 0 | CVPG 58,6 | 1,7 | 20% | 46,8 | 70,4 | 23 | | | | | | | | 23 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 58,4 | 2,5 | 4,3 | 8 | 0 | CVPG 58,4 | 1,9 | 20% | 46,7 | 70,1 | 8 | | | | | | | | 8 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 42,1 | 2,0 | 4,9 | 101 | 0 | CVPG 42,1 | 0,50 | 20% | 33,6 | 50,6 | 101 | | | | | | | | 101 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 38,3 | 3,2 | 8,2 | 60 | 0 | CVPG 38,3 | 1,00 | 20% | 30,6 | 46 | 60 | | | | | | | | 60 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 37,5 | 3,2 | 8,6 | 79 | 0 | CVPG 37,5 | 0,89 | 20% | 30 | 45 | 79 | | | | | | | | 79 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 51,4 | 2,3 | 4,5 | 234 | 0 | CVPG 51,4 | 0,37 | 20% | 41,1 | 61,7 | 234 | | | | | | | | 234 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 36,8 | 2,2 | 6,0 | 36 | 0 | CVPG 36,8 | 0,90 | 20% | 29,4 | 44,2 | 36 | | | | | | | | 36 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 43,9 | 2,8 | 6,4 | 7 | 0 | CVPG 43,9 | 2,7 | 20% | 35,1 | 52,7 | 7 | | | | | | | | 7 | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | | | | | | | | Traceability | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
| **(304) Progesterone** [nmol/L] | | | | 659 | | | | | | | | 650 | 621 | 96% | | | | | | | 659 | 549 | 83% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 44,6 | 8,2 | 18 | 659 | | | | | | | | 650 | 642 | 99% | CRV | 45,07 | 0,56 | 26% | 33,3 | 56,8 | 659 | 614 | 93% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 35,5 | 2,2 | 6,2 | 68 | 0 | CVPG | 35,5 | 0,66 | 20% | 28,4 | 42,6 | 68 | | | | | | | | | 68 | | |
| Other | | | | 9 | 0 | | | | | | | 0 | | | | | | | | | 9 | | |
| | | | | | | 3x 1/36, 1x 2/26, 1x 4/15, 2x 4/149, 1x 4/999, 1x 6/60 | | | | | | | | | 3x 1/36, 1x 2/26, 1x 4/15, 2x 4/149, 1x 4/999, 1x 6/60 | | | | | | | |
| **Sample B** | 7,66 | 0,91 | 12 | 659 | | | | | | | | 650 | 625 | 96% | CRV | 6,89 | 0,070 | 26% | 5,09 | 8,69 | 659 | 581 | 88% |
| (2) EIA (ELISA); (66) DRG | 8,65 | 0,33 | 3,8 | 34 | 0 | CVPG | 8,65 | 0,14 | 20% | 6,92 | 10,4 | 34 | | | | | | | | | 34 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 7,76 | 0,78 | 10 | 23 | 0 | CVPG | 7,76 | 0,40 | 20% | 6,2 | 9,32 | 23 | | | | | | | | | 23 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 8,92 | 0,45 | 5,0 | 8 | 0 | CVPG | 8,92 | 0,34 | 20% | 7,13 | 10,8 | 8 | | | | | | | | | 8 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 6,89 | 0,52 | 7,5 | 101 | 0 | CVPG | 6,89 | 0,13 | 20% | 5,51 | 8,27 | 101 | | | | | | | | | 101 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 7,04 | 0,81 | 11 | 60 | 0 | CVPG | 7,04 | 0,26 | 20% | 5,63 | 8,45 | 60 | | | | | | | | | 60 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 8,21 | 0,71 | 8,7 | 79 | 0 | CVPG | 8,21 | 0,20 | 20% | 6,56 | 9,86 | 79 | | | | | | | | | 79 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 8,03 | 0,53 | 6,6 | 234 | 0 | CVPG | 8,03 | 0,085 | 20% | 6,42 | 9,64 | 234 | | | | | | | | | 234 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 7,05 | 0,56 | 7,9 | 36 | 0 | CVPG | 7,05 | 0,23 | 20% | 5,64 | 8,46 | 36 | | | | | | | | | 36 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 6,55 | 0,85 | 13 | 7 | 0 | CVPG | 6,55 | 0,83 | 20% | 5,24 | 7,86 | 7 | | | | | | | | | 7 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 7,02 | 0,68 | 9,6 | 68 | 0 | CVPG | 7,02 | 0,20 | 20% | 5,61 | 8,43 | 68 | | | | | | | | | 68 | | |
| Other | | | | 9 | 0 | | | | | | | 0 | | | | | | | | | 9 | | |
| | | | | | | 3x 1/36, 1x 2/26, 1x 4/15, 2x 4/149, 1x 4/999, 1x 6/60 | | | | | | | | | 3x 1/36, 1x 2/26, 1x 4/15, 2x 4/149, 1x 4/999, 1x 6/60 | | | | | | | |
| **(305) Testosterone** [nmol/L] | | | | 836 | | | | | | | | 821 | 798 | 97% | | | | | | | 836 | 802 | 96% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 14,6 | 1,4 | 9,6 | 836 | | | | | | | | 821 | 807 | 98% | CRV | 13,82 | 0,14 | 30% | 9,67 | 18 | 836 | 821 | 98% |
| (2) EIA (ELISA); (66) DRG | 13,8 | 0,31 | 2,2 | 36 | 0 | CVPG | 13,8 | 0,13 | 22% | 10,7 | 16,9 | 36 | | | | | | | | | 36 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 12,5 | 0,86 | 6,8 | 44 | 0 | CVPG | 12,5 | 0,32 | 22% | 9,75 | 15,3 | 44 | | | | | | | | | 44 | | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 14,7 | 1,1 | 7,7 | 22 | 0 | CVPG | 14,7 | 0,59 | 22% | 11,4 | 18 | 22 | | | | | | | | | 22 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 15,0 | 0,96 | 6,4 | 117 | 0 | CVPG | 15 | 0,22 | 22% | 11,7 | 18,3 | 117 | | | | | | | | | 117 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 12,6 | 0,82 | 6,6 | 85 | 0 | CVPG | 12,6 | 0,22 | 22% | 9,82 | 15,4 | 85 | | | | | | | | | 85 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 14,5 | 1,4 | 9,8 | 96 | 0 | CVPG | 14,5 | 0,35 | 22% | 11,3 | 17,7 | 96 | | | | | | | | | 96 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 14,9 | 0,62 | 4,1 | 292 | 0 | CVPG | 14,9 | 0,088 | 22% | 11,6 | 18,2 | 292 | | | | | | | | | 292 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 15,7 | 0,79 | 5,0 | 39 | 0 | CVPG | 15,7 | 0,31 | 22% | 12,2 | 19,2 | 39 | | | | | | | | | 39 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 11,7 | 2,2 | 19 | 13 | 0 | CVPG | 11,7 | 1,5 | 22% | 9,12 | 14,3 | 13 | | | | | | | | | 13 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 15,9 | 1,5 | 9,4 | 77 | 0 | CVPG | 15,9 | 0,42 | 22% | 12,4 | 19,4 | 77 | | | | | | | | | 77 | | |
| Other | | | | 15 | 0 | | | | | | | 0 | | | | | | | | | 15 | | |
| | | | | | | 4x 1/36, 1x 2/26, 1x 2/60, 1x 2/214, 1x 4/15, 2x 4/40, 4x 4/98, 1x 4/183 | | | | | | | | | 4x 1/36, 1x 2/26, 1x 2/60, 1x 2/214, 1x 4/15, 2x 4/40, 4x 4/98, 1x 4/183 | | | | | | | |
| **Sample B** | 25,9 | 2,4 | 9,2 | 836 | | | | | | | | 821 | 804 | 98% | CRV | 23,9 | 0,25 | 30% | 16,7 | 31,1 | 836 | 811 | 97% |
| (2) EIA (ELISA); (66) DRG | 23,2 | 0,32 | 1,4 | 36 | 0 | CVPG | 23,2 | 0,13 | 22% | 18 | 28,4 | 36 | | | | | | | | | 36 | | |
| (3) FIA (FEIA, TRACE); (15) bioMérieux | 23,3 | 1,5 | 6,6 | 44 | 0 | CVPG | 23,3 | 0,57 | 22% | 18,1 | 28,5 | 44 | | | | | | | | | 44 | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | | | | | | | | Traceability | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
| **(305) Testosterone** [nmol/L] | | | | 836 | | | | | | | | 821 | 798 | 97% | | | | | | | 836 | 802 | 96% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample B** | 25,9 | 2,4 | 9,2 | 836 | | | | | | | | 821 | 804 | 98% | CRV | 23,9 | 0,25 | 30% | 16,7 | 31,1 | 836 | 811 | 97% |
| (3) FIA (FEIA, TRACE); (25) TOSOH | 30,1 | 2,0 | 6,5 | 22 | 0 | CVPG | 30,1 | 1,0 | 22% | 23,4 | 36,8 | 22 | | | | | | | | | 22 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 27,5 | 1,8 | 6,5 | 117 | 0 | CVPG | 27,5 | 0,41 | 22% | 21,4 | 33,6 | 117 | | | | | | | | | 117 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 22,6 | 1,7 | 7,5 | 85 | 0 | CVPG | 22,6 | 0,45 | 22% | 17,6 | 27,6 | 85 | | | | | | | | | 85 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 26,3 | 2,4 | 9,0 | 96 | 0 | CVPG | 26,3 | 0,59 | 22% | 20,5 | 32,1 | 96 | | | | | | | | | 96 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | 26,3 | 1,2 | 4,4 | 292 | 0 | CVPG | 26,3 | 0,17 | 22% | 20,5 | 32,1 | 292 | | | | | | | | | 292 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | 26,9 | 1,4 | 5,1 | 39 | 0 | CVPG | 26,9 | 0,54 | 22% | 20,9 | 32,9 | 39 | | | | | | | | | 39 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | 23,0 | 4,1 | 18 | 13 | 0 | CVPG | 23 | 2,8 | 22% | 17,9 | 28,1 | 13 | | | | | | | | | 13 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | 26,5 | 2,4 | 9,2 | 77 | 0 | CVPG | 26,5 | 0,68 | 22% | 20,6 | 32,4 | 77 | | | | | | | | | 77 | | |
| Other | | | | 15 | 0 | | | | | | | 0 | | | | | | | | | 15 | | |
| | | | | | | 4x 1/36, 1x 2/26, 1x 2/60, 1x 2/214, 1x 4/15, 2x 4/40, 4x 4/98, 1x 4/183 | | | | | | | | | | 4x 1/36, 1x 2/26, 1x 2/60, 1x 2/214, 1x 4/15, 2x 4/40, 4x 4/98, 1x 4/183 | | | | | | | | |
| **(306) 17-OH-progesterone** [nmol/L] | | | | 127 | | | | | | | | 117 | 111 | 95% | | | | | | | 127 | 96 | 76% |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 7,88 | 1,3 | 16 | 127 | | | | | | | | 117 | 114 | 97% | CRV | 6,024 | 0,072 | 44% | 3,37 | 8,68 | 127 | 96 | 76% |
| (1) RIA (IRMA); (36) Immunotech | 6,23 | 0,65 | 10 | 26 | 0 | CVPG | 6,23 | 0,31 | 33% | 4,17 | 8,29 | 26 | | | | | | | | | 26 | | |
| (1) RIA (IRMA); (47) Biosource | 9,50 | 1,2 | 13 | 5 | 0 | CVPG | 9,5 | 3,4 | 33% | 6,36 | 12,7 | 5 | | | | | | | | | 5 | | |
| (2) EIA (ELISA); (66) DRG | 7,95 | 0,72 | 9,1 | 11 | 0 | CVPG | 7,95 | 0,53 | 33% | 5,32 | 10,6 | 11 | | | | | | | | | 11 | | |
| (2) EIA (ELISA); (134) IBL | 8,07 | 0,97 | 12 | 43 | 0 | CVPG | 8,07 | 0,36 | 33% | 5,4 | 10,8 | 43 | | | | | | | | | 43 | | |
| (2) EIA (ELISA); (214) Demeditec | 9,35 | 0,97 | 10 | 5 | 0 | CVPG | 9,35 | 2,7 | 33% | 6,26 | 12,5 | 5 | | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | 8,32 | 0,44 | 5,3 | 27 | 0 | CVPG | 8,32 | 0,21 | 33% | 5,57 | 11,1 | 27 | | | | | | | | | 27 | | |
| Other | | | | 10 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | 1x 1/12, 1x 1/134, 1x 1/185, 1x 1/999, 1x 2/26, 2x 2/87, 1x 2/183, 1x 2/999, 1x 4/60 | | | | | | | | | | 1x 1/12, 1x 1/134, 1x 1/185, 1x 1/999, 1x 2/26, 2x 2/87, 1x 2/183, 1x 2/999, 1x 4/60 | | | | | | | | |
| **Sample B** | 18,9 | 4,0 | 21 | 127 | | | | | | | | 117 | 113 | 97% | CRV | 20,9 | 0,23 | 44% | 11,7 | 30,1 | 127 | 127 | 100% |
| (1) RIA (IRMA); (36) Immunotech | 17,7 | 2,6 | 15 | 26 | 0 | CVPG | 17,7 | 1,2 | 33% | 11,8 | 23,6 | 26 | | | | | | | | | 26 | | |
| (1) RIA (IRMA); (47) Biosource | 23,8 | 4,3 | 18 | 5 | 0 | CVPG | 23,8 | 12 | 33% | 15,9 | 31,7 | 5 | | | | | | | | | 5 | | |
| (2) EIA (ELISA); (66) DRG | 21,8 | 2,6 | 12 | 11 | 0 | CVPG | 21,8 | 1,9 | 33% | 14,6 | 29 | 11 | | | | | | | | | 11 | | |
| (2) EIA (ELISA); (134) IBL | 21,2 | 3,0 | 14 | 43 | 0 | CVPG | 21,2 | 1,1 | 33% | 14,2 | 28,2 | 43 | | | | | | | | | 43 | | |
| (2) EIA (ELISA); (214) Demeditec | 16,6 | 0,57 | 3,4 | 5 | 0 | CVPG | 16,6 | 1,6 | 33% | 11,1 | 22,1 | 5 | | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | 14,6 | 0,49 | 3,3 | 27 | 0 | CVPG | 14,6 | 0,23 | 33% | 9,78 | 19,5 | 27 | | | | | | | | | 27 | | |
| Other | | | | 10 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | 1x 1/12, 1x 1/134, 1x 1/185, 1x 1/999, 1x 2/26, 2x 2/87, 1x 2/183, 1x 2/999, 1x 4/60 | | | | | | | | | | 1x 1/12, 1x 1/134, 1x 1/185, 1x 1/999, 1x 2/26, 2x 2/87, 1x 2/183, 1x 2/999, 1x 4/60 | | | | | | | | |
| **(307) DHEA-S** [µmol/L] | | | | 462 | | | | | | | | 454 | 443 | 98% | | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | 14,5 | 1,9 | 13 | 462 | | | | | | | | 454 | 446 | 98% | | | | | | | 0 | | |
| (1) RIA (IRMA); (218) Immunotech (original) | 15,6 | 1,5 | 9,7 | 5 | 0 | CVPG | 15,6 | 4,3 | 21% | 12,3 | 18,9 | 5 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | 14,5 | 0,89 | 6,1 | 63 | 0 | CVPG | 14,5 | 0,27 | 21% | 11,4 | 17,6 | 63 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | 14,0 | 1,0 | 7,4 | 36 | 0 | CVPG | 14 | 0,42 | 21% | 11 | 17 | 36 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | 13,3 | 1,2 | 9,2 | 85 | 0 | CVPG | 13,3 | 0,32 | 21% | 10,5 | 16,1 | 85 | | | | | | | | | | | |

# Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

| Test | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | | | | | | | | Traceability | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ |
| **(307) DHEA-S** | [µmol/L] | | | | 462 | | | | | | | | 454 | 443 | 98% | | | | | | 0 | | |
| Samples and groups | | | | | | | | | | | | | | | | | | | | | | | |
| **Sample A** | | 14,5 | 1,9 | 13 | 462 | | | | | | | | 454 | 446 | 98% | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 16,0 | 1,1 | 6,7 | 192 | 0 | CVPG | 16 | 0,19 | 21% | 12,6 | 19,4 | 192 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | | 12,7 | 0,97 | 7,6 | 23 | 0 | CVPG | 12,7 | 0,50 | 21% | 10 | 15,4 | 23 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | | 10,9 | 1,5 | 14 | 16 | 0 | CVPG | 10,9 | 0,92 | 21% | 8,61 | 13,2 | 16 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 12,4 | 1,0 | 8,1 | 34 | 0 | CVPG | 12,4 | 0,42 | 21% | 9,79 | 15,1 | 34 | | | | | | | | | | |
| Other | | | | | 8 | 0 | | | | | | | 0 | | | | | | | | | | |
| | | | | | | | 1x 2/26, 1x 2/60, 3x 2/66, 1x 2/134, 1x 2/214, 1x 3/25 | | | | | | | | | | | | | | | |
| **Sample B** | | 15,3 | 2,1 | 14 | 462 | | | | | | | | 454 | 447 | 98% | | | | | | 0 | | |
| (1) RIA (IRMA); (218) Immunotech (original) | | 16,0 | 0,17 | 1,1 | 5 | 0 | CVPG | 16 | 0,48 | 21% | 12,6 | 19,4 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 14,9 | 0,85 | 5,7 | 63 | 0 | CVPG | 14,9 | 0,26 | 21% | 11,7 | 18,1 | 63 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 14,7 | 1,1 | 7,4 | 36 | 0 | CVPG | 14,7 | 0,45 | 21% | 11,6 | 17,8 | 36 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | | 13,7 | 0,98 | 7,1 | 85 | 0 | CVPG | 13,7 | 0,26 | 21% | 10,8 | 16,6 | 85 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 17,0 | 1,2 | 7,2 | 192 | 0 | CVPG | 17 | 0,22 | 21% | 13,4 | 20,6 | 192 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica) | | 13,6 | 0,89 | 6,5 | 23 | 0 | CVPG | 13,6 | 0,46 | 21% | 10,7 | 16,5 | 23 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | | 11,5 | 1,3 | 11 | 16 | 0 | CVPG | 11,5 | 0,81 | 21% | 9,08 | 14 | 16 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 13,3 | 1,1 | 8,1 | 34 | 0 | CVPG | 13,3 | 0,46 | 21% | 10,5 | 16,1 | 34 | | | | | | | | | | |
| Other | | | | | 8 | 0 | | | | | | | 0 | | | | | | | | | | |
| | | | | | | | 1x 2/26, 1x 2/60, 3x 2/66, 1x 2/134, 1x 2/214, 1x 3/25 | | | | | | | | | | | | | | | |